// App-Quantinova.ai

4544 : Updated analysis of circulating tumor cells (CTCs) in patients with urothelial cancer (UC) undergoing systemic treatment: Implications across the clinical stages.

Researchers

Presenter

  • Andrea Necchi

Principal Investigators

  • Emanuela Fina

  • Patrizia Giannatempo

  • Luigi Mariani

  • Maria Grazia Daidone

  • Elena Far

  • Daniele Raggi

  • Massimo Maffezzini

  • Nicola Nicolai

  • Roberto Salvioni

  • Alessandro M. Gianni

  • Vera Cappelletti

  • Maurizio Colecchia

  • Chiara Iacona

Medical Centers

  • Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Fondazione IRCCS Istituto Nazionale Tumori, Milan, ItalyFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • Activin A receptor type II-like 1

  • Kerbs von Lungren 6 antigen

  • Circulating tumor cells

Drug/Treatment

  • ascrinvacumab

  • Sorafenib

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved